[GeneFirst-Emerging] February 2026 Revenue: NT$36 Million (YoY +12.0%)
GeneFirst-Emerging announced its revenue for February 2026 reached NT$36 million, a 12.0% increase year-over-year. The revenue figures for the biotechnology company, which specializes in precision medicine, demonstrate stable growth in its genetic testing services business.
📋 Article Processing Timeline
- 📰 Published: February 1, 2026 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (1559h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:19 (16h 19m after Collected)
Stock Code: 6645
Company Name: GeneFirst-Emerging
Industry: Biotechnology and Medical Care
Data Month: 2026-02
Monthly Revenue: NT$35,863 thousand (NT$36 million)
Year-over-Year Change: +12.0%
Company Name: GeneFirst-Emerging
Industry: Biotechnology and Medical Care
Data Month: 2026-02
Monthly Revenue: NT$35,863 thousand (NT$36 million)
Year-over-Year Change: +12.0%
FAQ
What was GeneFirst-Emerging's revenue for February 2026?
GeneFirst-Emerging's revenue for February 2026 was NT$35,863 thousand, which is approximately NT$36 million.
How did GeneFirst-Emerging's February 2026 revenue compare to the previous year?
GeneFirst-Emerging's revenue in February 2026 showed a year-over-year increase of 12.0%.
What is the stock code for GeneFirst-Emerging?
The stock code for GeneFirst-Emerging is 6645.
In which industry does GeneFirst-Emerging operate?
GeneFirst-Emerging operates in the Biotechnology and Medical Care industry.
What specific month and year does the reported revenue data pertain to?
The reported revenue data pertains to the month of February in the year 2026.